Latest Breaking News On - Jon nugent - Page 1 : comparemela.com

Coeptis Therapeutics SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications

Coeptis Therapeutics SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jon nugentDavid schemeliaJason lohmuellerKarolinska institutetDave mehalickDivision of surgical oncology researchCoeptis pharmaceuticals incPrnewswire coeptis therapeutics holdings incExchange commissionCoeptis therapeutics holdings incCoeptis therapeutics incSecurities exchangeHoldings incUniversity of pittsburghNature communicationsDrug administration

Coeptis Therapeutics SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications

/PRNewswire/ Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy.

Jon nugentDave mehalickJason lohmuellerKarolinska institutetDavid schemeliaCoeptis pharmaceuticals incUniversity of pittsburghDrug administrationPrnewswire coeptis therapeutics holdings incNature communicationsCoeptis therapeutics incCoeptis therapeutics holdings incSecurities exchangeHoldings incDivision of surgical oncology researchExchange commission

Coeptis Therapeutics SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications

SNAP-CAR represents a major advance potentially expanding the targeting capabilities of chimeric antigen receptor T cells for various cancers and other indications WEXFORD, Pa., May 10, 2023. | June 15, 2023

Jon nugentJason lohmuellerDave mehalickKarolinska institutetDavid schemeliaUniversity of pittsburghDrug administrationPrnewswire coeptis therapeutics holdings incNature communicationsCoeptis therapeutics incCoeptis pharmaceuticals incCoeptis therapeutics holdings incSecurities exchangeHoldings incDivision of surgical oncology researchExchange commission

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

WESTON, Fla. and ANN ARBOR, Mich., April 20, 2023 /PRNewswire/ Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions,

United statesCasey mcdonaldStepheng marcusJon nugentSalim hayekFrankel cardiovascular centerUniversity of michigan healthCantex pharmaceuticals incKellogg eye centerUniversity of michiganRogel cancer centerPrnewswire cantex pharmaceuticals incUniversity hospitalTv therapeutics incMichigan medicineMedical director

Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics

Proposed transaction would provide Coeptis with two clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia and hospitalized respiratory infections, as. | April 18, 2023

David schemeliaColleen delaneyKarolinska institutetJon nugentDave mehalickCoeptis pharmaceuticals incCoeptis therapeutics incSecurities exchangeCoeptis therapeutics holdings incHoldings incUniversity of pittsburghPrnewswire coeptis therapeutics holdings incResearch developmentDeverra therapeutics incDrug administrationExchange commission